The World Health Organisation (WHO) has described 2025 as a challenging year, marked by unprecedented disruption following ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
In 2026, AI will continue threading itself into behavioral health, and the bar will rise sharply for what counts as ...
Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback